Effect of hypoxia-inducible factor-prolyl hydroxylase inhibitors on anemia in patients with CKD: a meta-analysis of randomized controlled trials including 2804 patients

References

• Collister D, Komenda P, Hiebert B, et al. The effect of erythropoietin-stimulating agents on health-related quality of life in anemia of chronic kidney disease: a systematic review and meta-analysis. Ann Intern Med. 2016;164(7):472–478.
   PubMed Web of Science ®Google Scholar
• Li S, Foley RN, Collins AJ. Anemia and cardiovascular disease, hospitalization, end stage renal disease, and death in older patients with chronic kidney disease. Int Urol Nephrol. 2005;37(2):395–402.
   PubMedGoogle Scholar
• Portoles J, Gorriz JL, Rubio E, et al.; NADIR-3 Study Group. The development of anemia is associated to poor prognosis in NKF/KDOQI stage 3 chronic kidney disease. BMC Nephrol. 2013;14:2.
   PubMed Web of Science ®Google Scholar
• Locatelli F, Pisoni RL, Combe C, et al. Anaemia in haemodialysis patients of five European countries: association with morbidity and mortality in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Nephrol Dial Transplant. 2004;19(1):121–132.
   PubMed Web of Science ®Google Scholar
• Regidor DL, Kopple JD, Kovesdy CP, et al. Associations between changes in hemoglobin and administered erythropoiesis-stimulating agent and survival in hemodialysis patients. J Am Soc Nephrol. 2006;17(4):1181–1191.
   PubMed Web of Science ®Google Scholar
• Wetmore JB, Li S, Yan H, et al. Predialysis anemia management and outcomes following dialysis initiation: A retrospective cohort analysis. Plos One. 2018;13(9):e203767.
   Web of Science ®Google Scholar
• Volkova N, Arab L. Evidence-based systematic literature review of hemoglobin/hematocrit and all-cause mortality in dialysis patients. Am J Kidney Dis. 2006;47(1):24–36.
   PubMed Web of Science ®Google Scholar
• Hamilton R, Hawley S. Quality of life outcomes related to anemia management of patients with chronic renal failure. Clin Nurse Spec. 2006;20(3):139–143.
   PubMed Web of Science ®Google Scholar
• Macdougall IC, White C, Anker SD, et al. Intravenous iron in patients undergoing maintenance hemodialysis. N Engl J Med. 2019;380(5):447–458.
   PubMed Web of Science ®Google Scholar
• Drueke TB, Locatelli F, Clyne N, et al. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med. 2006;355(20):2071–2084.
   PubMed Web of Science ®Google Scholar
• Pfeffer MA, Burdmann EA, Chen CY, et al. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med. 2009;361(21):2019–2032.
   PubMed Web of Science ®Google Scholar
• Bailie GR, Larkina M, Goodkin DA, Li Y, et al. Data from the Dialysis Outcomes and Practice Patterns Study validate an association between high intravenous iron doses and mortality. Kidney Int. 2015;87(1):162–168.
   PubMed Web of Science ®Google Scholar
• Krapf R, Hulter HN. Arterial hypertension induced by erythropoietin and erythropoiesis-stimulating agents (ESA). Clin J Am Soc Nephrol. 2009;4(2):470–480.
   PubMed Web of Science ®Google Scholar
• Robles NR. The safety of erythropoiesis-stimulating agents for the treatment of anemia resulting from chronic kidney disease. Clin Drug Investig. 2016;36(6):421–431.
   PubMed Web of Science ®Google Scholar
• Locatelli F, Nissenson AR, Barrett BJ, et al. Clinical practice guidelines for anemia in chronic kidney disease: problems and solutions. A position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int. 2008;74(10):1237–1240.
   PubMed Web of Science ®Google Scholar
• Del VL, Locatelli F. Anemia in chronic kidney disease patients: treatment recommendations and emerging therapies. Expert Rev Hematol. 2014;7(4):495–506.
   PubMed Web of Science ®Google Scholar
• Kaplan J. Roxadustat and anemia of chronic kidney disease. N Engl J Med. 2019;381(11):1070–1072.
   PubMed Web of Science ®Google Scholar
• NIH U.S. National Library of Medicine. Available from: https://clinicaltrials.gov.
   Google Scholar
• Chen N, Hao C, Peng X, et al. Roxadustat for anemia in patients with kidney disease not receiving dialysis. N Engl J Med. 2019;381(11):1001–1010.
   PubMed Web of Science ®Google Scholar
• Pergola PE, Spinowitz BS, Hartman CS, et al. Vadadustat, a novel oral HIF stabilizer, provides effective anemia treatment in nondialysis-dependent chronic kidney disease. Kidney Int. 2016;90(5):1115–1122.
   PubMed Web of Science ®Google Scholar
• Cizman B, Sykes AP, Paul G, et al. An exploratory study of daprodustat in erythropoietin-hyporesponsive subjects. Kidney Int Rep. 2018;3(4):841–850.
   PubMed Web of Science ®Google Scholar
• Chen N, Hao C, Liu BC, et al. Roxadustat treatment for anemia in patients undergoing long-term dialysis. N Engl J Med. 2019;381(11):1011–1022.
   PubMed Web of Science ®Google Scholar
• Holdstock L, Meadowcroft AM, Maier R, et al. Four-week studies of oral hypoxia-inducible factor-prolyl hydroxylase inhibitor gsk1278863 for treatment of anemia. J Am Soc Nephrol. 2016;27(4):1234–1244.
   PubMed Web of Science ®Google Scholar
• Parmar DV, Kansagra KA, Patel JC, et al. on behalf of the ZYAN1 Trial Investigators. Outcomes of desidustat treatment in people with anemia and chronic kidney disease: a phase 2 study. Am J Nephrol. 2019;49(6):470–478.
   PubMed Web of Science ®Google Scholar
• Akizawa T, Nangaku M, Yamaguchi T, et al. Enarodustat, conversion and maintenance therapy for anemia in hemodialysis patients: a randomized, placebo-controlled phase 2b trial followed by long-term trial. Nephron. 2019;143(2):77–85.
   PubMed Web of Science ®Google Scholar
• Macdougall IC, Akizawa T, Berns JS, et al. Effects of molidustat in the treatment of anemia in CKD. Clin J Am Soc Nephrol. 2019;14(1):28–39.
   PubMed Web of Science ®Google Scholar
• Martin ER, Smith MT, Maroni BJ, et al. Clinical trial of vadadustat in patients with anemia secondary to stage 3 or 4 chronic kidney disease. Am J Nephrol. 2017;45(5):380–388.
   PubMed Web of Science ®Google Scholar
• Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med. 2009;6(7):e1000100.
   PubMed Web of Science ®Google Scholar
• Higgins JP, Altman DG, Gotzsche PC, et al. Cochrane Statistical Methods Group. The Cochrane collaboration's tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928.
   PubMed Web of Science ®Google Scholar
• Akizawa T, Tsubakihara Y, Nangaku M, et al. Effects of daprodustat, a novel hypoxia-inducible factor prolyl hydroxylase inhibitor on anemia management in japanese hemodialysis subjects. Am J Nephrol. 2017;45(2):127–135.
   PubMed Web of Science ®Google Scholar
• Holdstock L, Cizman B, Meadowcroft AM, Biswas N, et al. Daprodustat for anemia: a 24-week, open-label, randomized controlled trial in participants with chronic kidney disease. Clin Kidney J. 2019;12(1):129–138.
   PubMed Web of Science ®Google Scholar
• Meadowcroft AM, Cizman B, Holdstock L, et al. Daprodustat for anemia: a 24-week, open-label, randomized controlled trial in participants on hemodialysis. Clin Kidney J. 2019;12(1):139–148.
   PubMed Web of Science ®Google Scholar
• Akizawa T, Iwasaki M, Otsuka T, et al. Roxadustat treatment of chronic kidney disease-associated anemia in Japanese patients not on dialysis: a phase 2, randomized, double-blind, placebo-controlled trial. Adv Ther. 2019;36(6):1438–1454.
   PubMed Web of Science ®Google Scholar
• Besarab A, Provenzano R, Hertel J, et al. Randomized placebo-controlled dose-ranging and pharmacodynamics study of roxadustat (FG-4592) to treat anemia in nondialysis-dependent chronic kidney disease (NDD-CKD) patients. Nephrol Dial Transplant. 2015;30(10):1665–1673.
   PubMed Web of Science ®Google Scholar
• Chen N, Qian J, Chen J, et al. Phase 2 studies of oral hypoxia-inducible factor prolyl hydroxylase inhibitor FG-4592 for treatment of anemia in China. Nephrol Dial Transplant. 2017;32(8):1373–1386.
   PubMed Web of Science ®Google Scholar
• Provenzano R, Besarab A, Sun CH, et al. Oral hypoxia-inducible factor prolyl hydroxylase inhibitor roxadustat (FG-4592) for the treatment of anemia in patients with CKD. CJASN. 2016;11(6):982–991.
   PubMed Web of Science ®Google Scholar
• Akizawa T, Nangaku M, Yamaguchi T, et al. A placebo-controlled, randomized trial of enarodustat in patients with chronic kidney disease followed by long-term trial. Am J Nephrol. 2019;49(2):165–174.
   PubMed Web of Science ®Google Scholar
• Akizawa T, Macdougall IC, Berns JS, et al. Long-term efficacy and safety of molidustat for anemia in chronic kidney disease: DIALOGUE extension studies. Am J Nephrol. 2019;49(4):271–280.
   PubMed Web of Science ®Google Scholar
• Mastrogiannaki M, Matak P, Keith B, et al. HIF-2alpha, but not HIF-1alpha, promotes iron absorption in mice. J Clin Invest. 2009;119(5):1159–1166.
   PubMed Web of Science ®Google Scholar
• Liu Q, Davidoff O, Niss K, et al. Hypoxia-inducible factor regulates hepcidin via erythropoietin-induced erythropoiesis. J Clin Invest. 2012;122(12):4635–4644.
   PubMed Web of Science ®Google Scholar
• Koury MJ, Haase VH. Anaemia in kidney disease: harnessing hypoxia responses for therapy. Nat Rev Nephrol. 2015;11(7):394–410.
   PubMed Web of Science ®Google Scholar
• Singh AK, Szczech L, Tang KL, et al. CHOIR Investigators. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med. 2006;355(20):2085–2098.
   PubMed Web of Science ®Google Scholar
• Pinto JP, Ribeiro S, Pontes H, et al. Erythropoietin mediates hepcidin expression in hepatocytes through EPOR signaling and regulation of C/EBPalpha. Blood. 2008;111(12):5727–5733.
   PubMed Web of Science ®Google Scholar
• Nicolas G, Chauvet C, Viatte L, et al. The gene encoding the iron regulatory peptide hepcidin is regulated by anemia, hypoxia, and inflammation. J Clin Invest. 2002;110(7):1037–1044.
   PubMed Web of Science ®Google Scholar
• Gordeuk VR, Miasnikova GY, Sergueeva AI, et al. Chuvash polycythemia VHLR200W mutation is associated with down-regulation of hepcidin expression. Blood. 2011;118(19):5278–5282.
   PubMed Web of Science ®Google Scholar
• Nakhoul G, Simon JF. Anemia of chronic kidney disease: Treat it, but not too aggressively. Cleve Clin J Med. 2016;83(8):613–624.
   PubMed Web of Science ®Google Scholar
• Locatelli F, Del VL. New strategies for anaemia management in chronic kidney disease. Contrib Nephrol. 2017;189:184–188.
   PubMed Web of Science ®Google Scholar
• Malyszko J, Malyszko JS, Mysliwiec M. Hyporesponsiveness to erythropoietin therapy in hemodialyzed patients: potential role of prohepcidin, hepcidin, and inflammation. Ren Fail. 2009;31(7):544–548.
   PubMed Web of Science ®Google Scholar
• Santos-Silva A, Ribeiro S, Reis F, et al. Hepcidin in chronic kidney disease anemia. Vitam Horm. 2019;110:243–264.
   PubMed Web of Science ®Google Scholar
• Tanaka T, Nangaku M. Recent advances and clinical application of erythropoietin and erythropoiesis-stimulating agents. Exp Cell Res. 2012;318(9):1068–1073.
   PubMed Web of Science ®Google Scholar
• Szczech LA, Barnhart HX, Inrig JK, et al. Secondary analysis of the CHOIR trial epoetin-alpha dose and achieved hemoglobin outcomes. Kidney Int. 2008;74(6):791–798.
   PubMed Web of Science ®Google Scholar
• Solomon SD, Uno H, Lewis EF, et al. Erythropoietic response and outcomes in kidney disease and type 2 diabetes. N Engl J Med. 2010;363(12):1146–1155.
   PubMed Web of Science ®Google Scholar
• Schodel J, Ratcliffe PJ. Mechanisms of hypoxia signalling: new implications for nephrology. Nat Rev Nephrol. 2019;15(10):641–659.
   PubMed Web of Science ®Google Scholar